Last reviewed · How we verify

Glargine & Glulisine

Cairo University · FDA-approved active Small molecule Quality 5/100

Glargine & Glulisine is a Small molecule drug developed by Cairo University. It is currently FDA-approved. Also known as: lantus, apidra.

At a glance

Generic nameGlargine & Glulisine
Also known aslantus, apidra
SponsorCairo University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Glargine & Glulisine

What is Glargine & Glulisine?

Glargine & Glulisine is a Small molecule drug developed by Cairo University.

Who makes Glargine & Glulisine?

Glargine & Glulisine is developed and marketed by Cairo University (see full Cairo University pipeline at /company/cairo-university).

Is Glargine & Glulisine also known as anything else?

Glargine & Glulisine is also known as lantus, apidra.

What development phase is Glargine & Glulisine in?

Glargine & Glulisine is FDA-approved (marketed).

Related